Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Actas Dermo-Sifiliográficas · 2025
DOI: 10.1016/j.ad.2024.12.027 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Actas Dermo-Sifiliográficas, 2025. Verfasst von O Al-Wattar-Ceballos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. Electronic address: oalwattar@sescam.jccm.es. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Interleukin-17. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that is difficult to manage, requiring the use of biologic drugs such as anti-TNFα and anti-interleukin 17 (anti-IL17). The aim of our review is to evaluate the safety and efficacy profile of anti-IL17 drugs in patients with HS. MATERIALS AND METHODS: We conducted a systematic review with subsequent meta-analysis following the population, intervention, comparison, outcome and type of study (PICOS) method. We included only randomized clinical trials with placebo (S) that included individuals with HS ≥18 years old (P), and who had been on placebo (C) OR, an anti-IL17 biologic drug (I) to measure safety and efficacy outcomes (O). Search was conducted across multiple databases: PubMed, Scopus, and the Cochrane Central Register of Controlled Trials. The risk of bias of each study, publication bias, sensitivity analysis, and certainty of evidence were determined. RESULTS: A total of 320 bibliographic references were obtained, 4 of which met the inclusion criteria. Compared to placebo, the meta-analysis showed a significantly higher percentage of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) OR, of 1.96 [1.79-2.15], a greater decrease in DLQI, MD -1.92 [-2.68,-1.16] and an increase in adverse effects; OR, 1.21 [1.09, 1.34], particularly due to Candida infections; OR, 5.61 [2.66-11.83]. CONCLUSIONS: Treatment with anti-IL17 biologic drugs is effective in patients with moderate-to-severe HS. Although these drugs are safe, they should be monitored due to the risk of infections, mainly candidiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. Electronic address: oalwattar@sescam.jccm.es.
- Dermatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
Zitieren
APA
Al-Wattar-Ceballos, O., Martínez-Montalvo, L., & Carmona-Rodríguez, M. (2025). Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2024.12.027
Vancouver
Al-Wattar-Ceballos O, Martínez-Montalvo L, Carmona-Rodríguez M. Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Actas Dermo-Sifiliográficas. 2025. doi:10.1016/j.ad.2024.12.027
BibTeX
@article{AlWattarCeballos2025,
author = {Al-Wattar-Ceballos, O and Martínez-Montalvo, L and Carmona-Rodríguez, M},
title = {Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials},
journal = {Actas Dermo-Sifiliográficas},
year = {2025},
doi = {10.1016/j.ad.2024.12.027}
}
EUVIMED